Immunome (IMNM) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunome (IMNM) has outperformed Vera Therapeutics (VERA) over the past year, gaining 37.8% versus a loss of 2.5%. Over five years, VERA leads with a +98.1% price change compared with +9.7% for IMNM. Immunome is the larger company by market cap ($2.31 billion vs $2.14 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | VERA |
|---|---|---|
| Share price | $19.56 | $29.71 |
| Market cap | $2.31B | $2.14B |
| 1-day change | +1.29% | -0.08% |
| YTD return | -10.10% | -41.29% |
| 1-year return | +37.83% | -2.52% |
| 5-year return | +9.65% | +98.07% |
| EPS (TTM) | $-2.52 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | — |
| Revenue growth (YoY) | -23.23% | — |
| Net income (latest FY) | $-212.39M | $-299.62M |
| Operating margin | -3228.83% | — |
| Net margin | -3059.99% | — |
| 52-week high | $30.06 | $56.05 |
| 52-week low | $13.49 | $23.05 |
| Distance from 52-week high | -34.93% | -47.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +79.96% | +160.90% |
| Average volume | 1.20M | 2.21M |
| Shares outstanding | 118.00M | 72.06M |
| Employees | 247 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed VERA by 40.4 percentage points over the past year.
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
IMNM vs VERA FAQ
Which is bigger, Immunome or Vera Therapeutics?
Immunome (IMNM) is larger, with a market capitalization of $2.31B compared with $2.14B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, IMNM or VERA?
IMNM returned +37.83% over the past 12 months, compared with -2.52% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.